IDEXX Laboratories (IDXX) Q4 2010 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2010 earnings summary
9 Nov, 2026Executive summary
FY2010 revenue rose 7.0% to $1.103B; operating income increased to $203.9M and net income attributable to shareholders to $141.3M.
Q4 revenue was $283.8M, operating income $50.8M, net income attributable to shareholders $36.4M and diluted EPS $0.62.
Financial highlights
FY2010 gross profit was $578.6M versus $526.3M in 2009; revenue was $1.103B versus $1.032B.
FY2010 diluted EPS was $2.37 versus $2.01; net income attributable to shareholders was $141.3M versus $122.2M.
Operating cash flow was $178.8M; cash and cash equivalents ended the year at $156.9M.
Outlook and guidance
2011 capital expenditure plan was ~$45M, including ~$10.5M for headquarters renovation and expansion.
Growth was expected to remain pressured until broad economic conditions improve in the U.S. and Europe; available cash, operating cash flow and borrowing capacity were expected to fund near-term and long-term needs.
Latest events from IDEXX Laboratories
- Revenue grew 16%, with 10% organic growth and adjusted EPS up 13%.IDXX
Q4 2005 - Revenue grew 25%, while margin pressure and Navigator charges weighed on earnings.IDXXQ4 2007
- FY08 growth lifted revenue and earnings, while Q4 softened and regulatory risks mounted.IDXXQ4 2008
- Revenue rose 16%, organic growth accelerated, and adjusted EPS increased 23%.IDXXQ4 2006
- Direct-sales transition weighed on reported profit, but adjusted operating income grew 9.1%.IDXXQ4 2014
- CAG-led organic growth lifted FY13 revenue 6.7%, despite weaker LPD profitability.IDXXQ4 2013
- CAG growth lifted FY12 revenue and margins despite currency and livestock-testing headwinds.IDXXQ4 2012
- Recurring CAG diagnostics drove growth as FX headwinds and a software impairment tempered FY15 results.IDXXQ4 2015
- FY11 growth and stronger cash flow, offset by market and currency risks.IDXXQ4 2011